Fig. 2
From: Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus
Fidaxomicin is an inhibitor of ZIKV RdRp. a Schematic diagram of the NS5 and RdRp expression vectors. b–e SPR assay to examine and characterize the binding of fidaxomicin or ribavirin to either ZIKV NS5 or RdRp, using a BIAcore T100 system. ZIKV NS5 or RdRp protein was immobilized on a CM5 chip, respectively. The analytes were consisting of serial dilutions of fidaxomicin or ribavirin, as indicated. The Kd values presented in b and d were calculated via the BIAcore T100 analysis software (BIAevaluation Version 3.1). f The polymerase activity of NS5 at gradient concentrations ranging between 0 and 20 nM (left) and inhibition of the polymerase activity of NS5 (20 nM) gradient concentrations of fidaxomicin ranging between 0 and 200 μM (right). Constant concentrations of Primer/Template (10 nM) were used in both assays. The red word “20 nt” indicates location of the unextended primer, and “28 nt” indicates location of the full-length product. g Quantification of the NS5 activities tested in f (right panel at bottom) using gray scale scanning by Image J. Data are representative of three independent experiments